↓ Skip to main content

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

Overview of attention for article published in Retrovirology, December 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (93rd percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

blogs
1 blog
twitter
3 X users
patent
2 patents
facebook
1 Facebook page

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
25 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains
Published in
Retrovirology, December 2012
DOI 10.1186/1742-4690-9-104
Pubmed ID
Authors

Lu Lu, Chungen Pan, Yuan Li, Hong Lu, Wu He, Shibo Jiang

Abstract

Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate virions away from cells. Although soluble CD4 (sCD4) can inactivate laboratory-adapted HIV-1 strains, it fails to reduce the viral loads in clinical trials because of its low potency against primary isolates and tendency to enhance HIV-1 infection at low concentration. Thus, it is essential to design a better HIV inactivator with improved potency for developing new anti-HIV therapeutics that can actively attack the virus in the circulation before it attaches to and enter into the target cell.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 25 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 25 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 24%
Researcher 4 16%
Student > Postgraduate 3 12%
Student > Master 3 12%
Student > Doctoral Student 2 8%
Other 4 16%
Unknown 3 12%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 24%
Medicine and Dentistry 5 20%
Agricultural and Biological Sciences 3 12%
Pharmacology, Toxicology and Pharmaceutical Science 2 8%
Chemistry 2 8%
Other 4 16%
Unknown 3 12%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 June 2022.
All research outputs
#1,908,750
of 22,714,025 outputs
Outputs from Retrovirology
#79
of 1,104 outputs
Outputs of similar age
#18,659
of 277,905 outputs
Outputs of similar age from Retrovirology
#3
of 17 outputs
Altmetric has tracked 22,714,025 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,104 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,905 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.